Differential transforming growth factor-β secretion in adenocarcinoma and squamous cell carcinoma of the uterine cervix

Gynecologic Oncology

Volumn 64, Issue 3, 1997, Pages 477-480

  Santin, Alessandro D ^a,d,e   Hermonat, Paul L ^a   Hiserodt, John C ^b   Fruehauf, John ^c   Schranz, Viktor ^b   Barclay, David ^a   Pecorelli, Sergio ^d   Parham, Groesbeck P ^a  

^a UNIVERSITY OF ARKANSAS AT LITTLE ROCK   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Oncotech Inc   (United States)

^d UNIVERSITY OF BRESCIA   (Italy)

^e UNIVERSITY OF ARKANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ADENOCARCINOMA; ANIMAL CELL; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; EFFECTOR CELL; FEMALE; HUMAN; IMMUNE RESPONSE; KERATINOCYTE; PRIORITY JOURNAL; RISK FACTOR; SQUAMOUS CELL CARCINOMA; SUPERNATANT; TUMOR GROWTH; UTERINE CERVIX CARCINOMA; VIRUS INFECTION; WART VIRUS;

EID: 0031105963     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.4579     Document Type: Article

References (27)

1. 1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer Statistics 1996. CA46:5-27, 1996
2. 2. Eifel PJ, Morris M, Oswald MJ, Wharton JT, Delclos L: Adenocarcinoma of the uterine cervix: Prognosis and patterns of failure in 367 cases. Cancer 65:2507-2514, 1990
3. 3. Brinton LA: Epidemiology of Cervical Cancer: Overview, in Munoz N, Bosh F, Shah KV, Meheus A (eds): The Epidemiology of Human Papillomavirus and Cervical Cancer. Lyon, France, IARC, 1992, No. 119, pp 3-23
4. 4. Kinlen LJ, Sheil AGR, Peto J, Doll R: Collaborative United Kingdom-Australian study of cancer in patients treated with immunosuppressive drugs. BMJ 2:1461-1466, 1979
5. 5. Penn I: Cancers of the anogenital region in renal transplant recipients: Analysis of 65 cases. Cancer 58:611-616, 1988
6. 6. Rellihan MA, Dooley DP, Burke TW, et al. Rapidly progressing cervical cancer in a patient with human immunodeficiency virus infection. Gynecol Oncol 36:435-438, 1990
7. 7. Eide TJ: Cancer of the uterine cervix in Norway by histologic type, 1970-84. J Natl Cancer Inst 79:199-205 1987
8. 8. Silcocks PBS, Thornton-Jones H, Murphy M: Squamous and adenocarcinoma of the uterine cervix: A comparison using routine data. Br J Cancer 55:321-325 1987
9. 9. Kleine W, Rau K, Schwoeorer D, Pfleiderer A: Prognosis of the adenocarcinoma of the cervix uteri: A comparative study. Gynecol Oncol 35:145-149, 1989
10. 10. Hopkins MP, Morley GW: A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet Gynecol 77:912-917, 1991
11. 11. Korhonen MO: Adenocarcinoma of the uterine cervix: Prognosis and prognostic significance of histology. Cancer 53:1760-1763, 1984
12. 12. Randall ME, Constable WC, Hahn SS, Kim JA, Mills SE: Results of the radiotherapeutic management of carcinoma of the cervix with emphasis on the influence of histologic classification. Cancer 62:48-53, 1988
13. 13. Milsom I, Friberg LG: Primary adenocarcinoma of the uterine cervix: A clinical study. Cancer 52:942-947, 1983
14. 14. De Martin R, Haendler B, Hofer-Warbinex, Gaugitsch H, Wrann M, Schlusenere H, Seifert JM, Bodmer S, Fontana A, Hofer E: Complementary DNA for human glioblastoma-derived T cell suppressor factor β, a novel member of the transforming growth factor-β family. EMBO J 6:3673-3677, 1987
15. 15. Derynck R, Jarret JA, Chen EY, Eaton DH, Bell JR, Assoian RK, Roberts AB, Sporn MB, Goeddel DV: Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature 316:701-705, 1985
16. 16. Berek JS, Martinez-Maza O: Molecular and biologic factors in the pathogenesis of ovarian cancer. J Reproduc Med 39:241-248, 1994
17. 17. Massague J: The transforming growth factor-β family. Annu Rev Cell Biol 6:597-624, 1990
18. 1. Cancer Res 50:7324-7332, 1990
19. 19. Tada T, Ohzeki S, Utsumi K, Takiuchi H, Muramatsu M, Li X-F, Shimizu J, Fujiwara H, Hamaoka T: Transforming growth factor-β induced inhibition of T cell function. J Immunol 146:1077-1082, 1991
20. + T and NK cells. J Exp Med 180:1937-1942, 1994
21. 1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 87:1486-1490, 1990
22. 2 antisense gene modified tumor cells eradicates intracranial gliomas. Proc AACR, 1995 (abstract)
23. 23. Dorigo O, Shawler DL, Roiston I, Sobol RE, Fakhray H: Transforming growth factor beta (TGF-β) inhibits effect of IL-2 gene therapy in TGF-β producing tumors. Proc AACR, 1995 (abstract)
24. 2 in human papillomavirus (HPV)-associated lesions of the uterine cervix. Gynecol Oncol 54:349-356, 1994
25. 2: cDNA cloning and sequence analysis. DNA 7:1-8, 1988
26. 26. Akhurst RJ, Fitzpatrick DR, Gatherer D, Lehnert SA, Millan FA: Transforming growth factor-βs in mammalian embryogenesis. Prog Growth Factor Res 2:153-168, 1991
27. 1. Cancer Res 52:1386-1392, 1992